Bausch + Lomb (NYSE:BLCO) PT Raised to $15.50

Bausch + Lomb (NYSE:BLCO) had its price target raised by research analysts at Evercore ISI from $15.00 to $15.50 in a note issued to investors on Tuesday, Benzinga reports. The firm presently has an “in-line” rating on the stock. Evercore ISI’s price target points to a potential upside of 5.73% from the company’s current price.

BLCO has been the subject of a number of other research reports. Evercore reduced their price objective on Bausch + Lomb from $17.00 to $15.00 and set an “in-line” rating for the company in a research note on Thursday, May 2nd. HC Wainwright reiterated a “buy” rating and issued a $20.00 price target on shares of Bausch + Lomb in a research report on Thursday, May 2nd. Royal Bank of Canada lowered their price objective on shares of Bausch + Lomb from $20.00 to $18.00 and set an “outperform” rating on the stock in a research report on Monday, April 22nd. Morgan Stanley raised shares of Bausch + Lomb from an “equal weight” rating to an “overweight” rating and upped their target price for the company from $16.00 to $18.00 in a report on Monday, May 6th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Bausch + Lomb in a report on Wednesday, May 1st. Five analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $18.95.

Bausch + Lomb Stock Performance

NYSE BLCO opened at $14.66 on Tuesday. The firm’s fifty day moving average price is $14.87 and its 200 day moving average price is $15.32. Bausch + Lomb has a 12 month low of $13.16 and a 12 month high of $21.23. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.70 and a quick ratio of 1.03. The company has a market capitalization of $5.16 billion, a price-to-earnings ratio of -15.27, a price-to-earnings-growth ratio of 1.47 and a beta of 0.48.

Bausch + Lomb (NYSE:BLCO) last issued its quarterly earnings data on Wednesday, May 1st. The company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by ($0.02). Bausch + Lomb had a positive return on equity of 3.60% and a negative net margin of 7.81%. The firm had revenue of $1.10 billion for the quarter, compared to analysts’ expectations of $1.06 billion. During the same period in the previous year, the business posted $0.10 EPS. The business’s revenue for the quarter was up 18.0% compared to the same quarter last year. On average, sell-side analysts expect that Bausch + Lomb will post 0.64 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Bausch + Lomb

A number of institutional investors have recently added to or reduced their stakes in the business. Renaissance Capital LLC raised its stake in shares of Bausch + Lomb by 27.3% during the 4th quarter. Renaissance Capital LLC now owns 22,407 shares of the company’s stock worth $382,000 after buying an additional 4,801 shares in the last quarter. Fore Capital LLC purchased a new position in Bausch + Lomb in the first quarter worth $384,000. Quadrature Capital Ltd acquired a new stake in Bausch + Lomb in the third quarter valued at $466,000. Jump Financial LLC boosted its position in shares of Bausch + Lomb by 478.0% during the 4th quarter. Jump Financial LLC now owns 87,100 shares of the company’s stock worth $1,486,000 after purchasing an additional 72,030 shares in the last quarter. Finally, Allianz Asset Management GmbH acquired a new position in shares of Bausch + Lomb during the 4th quarter worth $1,706,000. Hedge funds and other institutional investors own 11.07% of the company’s stock.

Bausch + Lomb Company Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.